Benzinga | Aug 10, 2021 10:38AM EDT

Truist Securities Maintains Buy on Axsome Therapeutics, Lowers Price Target to $160

Truist Securities analyst Joon Lee maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $200 to $160.